Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

BACKGROUND: Immunotherapies, specifically those based on immune checkpoint inhibitors, have shown promising activity in multiple tumor types. Other than mifamurtide (MEPACT®) for osteosarcoma approved by European Medicines Agency, there are no approved immunotherapies for sarcomas. METHODS: We analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Groisberg, Roman, Hong, David S., Behrang, Amini, Hess, Kenneth, Janku, Filip, Piha-Paul, Sarina, Naing, Aung, Fu, Siqing, Benjamin, Robert, Patel, Shreyaskumar, Somaiah, Neeta, Conley, Anthony, Meric-Bernstam, Funda, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735899/
https://www.ncbi.nlm.nih.gov/pubmed/29254498
http://dx.doi.org/10.1186/s40425-017-0301-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735899/
https://www.ncbi.nlm.nih.gov/pubmed/29254498
http://dx.doi.org/10.1186/s40425-017-0301-y

Ejemplares similares